About BVF Partners
BVF Partners is a private equity firm founded in 1993. It is primarily based in San Francisco, United States. In the last 12 months, it has participated in 11 funding rounds.
Overall BVF Partners portfolio has seen 42 IPOs and 24 acquisitions, namely X4 Pharmaceuticals, Ideaya Biosciences and Blueprint Medicines. A lot of funds co-invest with BVF Partners, with names like Janus Henderson Investors sharing a substantial percentage of its portfolio.
BVF Partners has a team of 8 people, including 2 partners.
Key Metrics
BVF Partners' Portfolio
They have invested in a total of 99 companies. Their most recent investment was in caspiantherapeutics.com (Series C round) on Sep 09, 2026. Here is the most recent investment by BVF Partners:Date | Company | Round | Amount | Co-Investors |
|---|---|---|---|---|
Sep 09, 2026 | Series C | 3460 | ||
Aug 10, 2026 | Series B | 9907 | ||
Aug 05, 2026 | Series B | 3131 | ||
Jun 02, 2026 | Series B | 9005 |
Here is the portfolio snapshot of BVF Partners:
Investments by Year
The maximum number of investments were made in 2026
Team profile of BVF Partners
BVF Partners has a team of 8 members including 2 Partners and 2 Principals located in United States. BVF Partners' team does not sit on the board of any company as of now.Here is a list of all team members in BVF Partners:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | San Francisco | - | ||
Partner | San Francisco | - | ||
Principal | San Francisco | - | ||
Principal | California | - | ||
Advisor | San Francisco | - | ||
Analyst | San Francisco | - | ||
Analyst | United States | - | - | |
Analyst | New Haven | - |
Co-investors of BVF Partners
Over the past 33 years, 222 investors have co-invested in BVF Partners's portfolio companies.
- Top Co-investors of BVF Partners: 222 investors entered a company along with BVF Partners. These include investors like Janus Henderson Investors (23 companies).
BVF Partners News
•
Superluminal Medicines Secures $60 Million for Rare Obesity Therapy DevelopmentPharmaceutical Business Review•Sep 04, 2026•Deep Track Capital, Insight Partners, Nvidia, Cooley and 9 others
•
Contraline Raises $92.5 Million Series B to Advance NES/T Male Contraceptive DevelopmentVentureburn•Jun 02, 2026•Invus, Contraline, Lumira Ventures, RA Capital Management and 4 others
•
Entera Bio Announces Pricing of $10.0 Million Direct Investment Bakersfield•Apr 02, 2026•Entera Bio, BVF Partners
•
Colorado biotech Ambrosia lands $100M for oral GLP-1Endpoints•Mar 31, 2026•Ambrosia Biosciences, Blue Owl, Deep Track Capital, Samsara BioCapital and 8 others
•
Briggs Morrison's Crossbow Unveils $77M Series B for T Cell EngagersEndpoints•Mar 18, 2026•Crossbow, Arkin, MPM BioImpact, LifeLink Ventures and 11 others
•
•
Immunic Announces Oversubscribed Private Placement of up to USD 400 MillionPR Newswire•Feb 13, 2026•Immunic, BVF Partners, Immunic, B. Riley Securities
•
Foghorn Therapeutics Announces Closing of $50 Million Registered Direct FinancingGlobeNewswire•Jan 14, 2026•Foghorn Therapeutics, BVF Partners
•
Diagonal Therapeutics Announces $125 Million Series B FinancingBenzinga•Jan 08, 2026•Diagonal Therapeutics, Sanofi Ventures, Janus Henderson Investors, RV Invest and 13 others
•
Bambusa Therapeutics Completes Series A-2 Financing to Boost Bispecific ProgramsPR Newswire•Nov 17, 2025•RA Capital Management, Athos KG, Bambusa Therapeutics, Salvia and 7 others
